Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2-Reference-Cited by-同舟云学术

Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2

Published:2024-01 Issue: Volume:237 Page:115770
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Aiello Federica^ORCID,Balzano Federica,Uccello Barretta Gloria,D’Acquarica Ilaria,Mazzoccanti Giulia,Agranat Israel

Funder

University of Rome La Sapienza

University of Pisa

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference35 articles.

1. B. Singh, H. Ryan, T. Kredo, M. Chaplin, T. Fletcher, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 (Review), Cochrane Database of Systematic Reviews, 2021, Issue 2. Art. No.: CD013587 (Accessed 22 May 2023).

2. U.S. Food and Drug Administration. Letter of Emergency Use Authorization, March 28, 2020. Available at: 〈https://www.fda.gov/media/136534/download〉 (Accessed 22 May 2023).

3. U.S. Food and Drug Administration. Letter of Revocation of Emergency Use Authorization, June 15, 2020. Available at: 〈https://www.fda.gov/media/138945/download〉 (Accessed 22 May 2023).

4. Authorizations and Revocation of Emergency Use of Drugs During the COVID-19 Pandemic; Availability;Fed. Regist.,2020

5. European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. EMA/170590/2020, 01/04/2020. 〈https://www.ema.europa.eu/en/documents/press-release/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf〉 (Accessed 22 May 2023).